Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

UNKNOWN 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Stomach Neoplasms 23Colorectal Neoplasms 11Colonic Neoplasms 8Carcinoma, Hepatocellular 6Rectal Neoplasms 5Pancreatic Neoplasms 5Esophageal Squamous Cell Carcinoma 4Carcinoma, Non-Small-Cell Lung 4Breast Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Squamous Cell Carcinoma of Head and Neck 3Head and Neck Neoplasms 3Esophageal Neoplasms 3Biliary Tract Neoplasms 3HER2-positive Gastric Cancer 2Gallbladder Neoplasms 2Uterine Cervical Neoplasms 1Stage IA Pancreatic Adenocarcinoma 1Nasopharyngeal Carcinoma 1Mouth Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lung Neoplasms 1Klatskin Tumor 1Immunotherapy 1Gastric Adenocarcinoma 1Fruquintinib 1For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method 1Extrapancreatic Neuroendocrine Tumor 1Epstein-Barr Virus Infections 1Efficacy and Safety 1

Interventions

Thalidomide 1Temozolomide 1Tegafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Extrapancreatic Neuroendocrine Tumor × Tegafur × Clear all
NCT03204032 2017-06-29

A Study of Tegafur Combined With Temozolomide Versus Tegafur Combined With Temozolomide and Thalidomide in Subjects With Advanced Extrapancreatic Neuroendocrine Tumor

ChineseAMS

Phase 2 Unknown
60 enrolled
EndocrineGastrointestinalNET

Extrapancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡